PRSS21
gene geneOn this page
Also known as ESP-1TEST1
Summary
PRSS21 (serine protease 21, HGNC:9485) is a protein-coding gene on chromosome 16p13.3, encoding Testisin (Q9Y6M0). Could regulate proteolytic events associated with testicular germ cell maturation.
This gene encodes a cell-surface anchored serine protease, which is a member of the trypsin family of serine proteases. The encoded protein is predicted to be active on peptide linkages involving the carboxyl group of lysine or arginine. The encoded protein localizes to the cytoplasm and the plasma membrane of premeiotic testicular germ cells and may be involved in progression of testicular tumors of germ cell origin. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Source: NCBI Gene 10942 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 64 total
- MANE Select transcript:
NM_006799
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:9485 |
| Approved symbol | PRSS21 |
| Name | serine protease 21 |
| Location | 16p13.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ESP-1, TEST1 |
| Ensembl gene | ENSG00000007038 |
| Ensembl biotype | protein_coding |
| OMIM | 608159 |
| Entrez | 10942 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 6 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined
ENST00000005995, ENST00000450020, ENST00000570594, ENST00000570629, ENST00000571141, ENST00000574265, ENST00000574813, ENST00000575199, ENST00000575739, ENST00000577043, ENST00000943033, ENST00000943034
RefSeq mRNA: 4 — MANE Select: NM_006799
NM_001270452, NM_006799, NM_144956, NM_144957
CCDS: CCDS10478, CCDS45388
Canonical transcript exons
ENST00000005995 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000664443 | 2820955 | 2821109 |
| ENSE00000873872 | 2821366 | 2821719 |
| ENSE00001854828 | 2817237 | 2817332 |
| ENSE00003470635 | 2818677 | 2818969 |
| ENSE00003628602 | 2817801 | 2817966 |
| ENSE00003636758 | 2817430 | 2817456 |
Expression profiles
Bgee: expression breadth ubiquitous, 121 present calls, max score 97.84.
FANTOM5 (CAGE): breadth broad, TPM avg 1.4977 / max 56.7990, expressed in 230 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 152305 | 0.8179 | 173 |
| 152307 | 0.4767 | 125 |
| 152303 | 0.0818 | 42 |
| 152304 | 0.0701 | 40 |
| 152302 | 0.0512 | 26 |
Top tissues by expression
131 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right testis | UBERON:0004534 | 97.84 | gold quality |
| left testis | UBERON:0004533 | 97.17 | gold quality |
| testis | UBERON:0000473 | 96.88 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 89.42 | gold quality |
| granulocyte | CL:0000094 | 85.42 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 83.12 | gold quality |
| bone marrow | UBERON:0002371 | 77.24 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 76.15 | gold quality |
| monocyte | CL:0000576 | 75.79 | gold quality |
| leukocyte | CL:0000738 | 75.71 | gold quality |
| gall bladder | UBERON:0002110 | 75.07 | gold quality |
| bone marrow cell | CL:0002092 | 74.30 | gold quality |
| right uterine tube | UBERON:0001302 | 73.51 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 72.66 | gold quality |
| minor salivary gland | UBERON:0001830 | 71.66 | gold quality |
| blood | UBERON:0000178 | 71.57 | gold quality |
| lymph node | UBERON:0000029 | 71.11 | gold quality |
| fallopian tube | UBERON:0003889 | 71.11 | gold quality |
| spleen | UBERON:0002106 | 70.25 | gold quality |
| right lung | UBERON:0002167 | 69.89 | gold quality |
| tonsil | UBERON:0002372 | 69.47 | gold quality |
| prostate gland | UBERON:0002367 | 69.24 | gold quality |
| vermiform appendix | UBERON:0001154 | 67.76 | gold quality |
| esophagus mucosa | UBERON:0002469 | 66.86 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 66.50 | gold quality |
| left uterine tube | UBERON:0001303 | 64.57 | gold quality |
| body of pancreas | UBERON:0001150 | 63.81 | gold quality |
| duodenum | UBERON:0002114 | 63.70 | gold quality |
| vagina | UBERON:0000996 | 63.00 | gold quality |
| lung | UBERON:0002048 | 62.37 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7249 | yes | 10.86 |
| E-ANND-3 | no | 1.79 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
9 targeting PRSS21, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-1-3P | 99.93 | 72.35 | 1914 |
| HSA-MIR-206 | 99.93 | 72.50 | 1893 |
| HSA-MIR-613 | 99.91 | 71.50 | 1710 |
| HSA-MIR-556-3P | 99.74 | 68.75 | 1203 |
| HSA-MIR-4708-3P | 99.51 | 67.99 | 870 |
| HSA-MIR-6128 | 99.33 | 67.83 | 1581 |
| HSA-MIR-3173-5P | 97.35 | 65.82 | 1282 |
| HSA-MIR-6799-3P | 97.35 | 65.60 | 1302 |
| HSA-MIR-2861 | 95.24 | 65.47 | 1056 |
Literature-anchored findings (GeneRIF, showing 5)
- Loss of Testisin is caused, at least in part, by DNA hypermethylation and histone deacetylation, and suggest a tumour suppressor role for Testisin in testicular tumorigenesis. (PMID:15685234)
- The results demonstrate for the first time that aberrant methylation of specific CpG sites near the transcription initiation site is an important factor in testisin gene silencing in TGCT. (PMID:16810501)
- These data suggest that aberrant regulation of PRSS21 may underlie certain secondary male infertility syndromes, such as “easily decapitated” spermatozoa in humans. (PMID:19571264)
- Testisin may promote carcinogenesis by inhibiting tumor suppressor activity of maspin. (PMID:20211623)
- Testisin activates PAR-2, inducing PAR-2 loss from the cell surface, internalization, and cellular signaling. (PMID:25519908)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Prss21 | ENSMUSG00000024116 |
| rattus_norvegicus | Prss21 | ENSRNOG00000047969 |
| drosophila_melanogaster | Sb | FBGN0003319 |
| drosophila_melanogaster | CG17242 | FBGN0250841 |
Paralogs (17): PRSS22 (ENSG00000005001), TMPRSS11E (ENSG00000087128), HPN (ENSG00000105707), TMPRSS13 (ENSG00000137747), ST14 (ENSG00000149418), TMPRSS11D (ENSG00000153802), TMPRSS15 (ENSG00000154646), TMPRSS3 (ENSG00000160183), TMPRSS5 (ENSG00000166682), TMPRSS7 (ENSG00000176040), TMPRSS9 (ENSG00000178297), TMPRSS2 (ENSG00000184012), TMPRSS11B (ENSG00000185873), TMPRSS6 (ENSG00000187045), TMPRSS11A (ENSG00000187054), TMPRSS11F (ENSG00000198092), PRSS41 (ENSG00000215148)
Protein
Protein identifiers
Testisin — Q9Y6M0 (reviewed: Q9Y6M0)
Alternative names: Eosinophil serine protease 1, Serine protease 21
All UniProt accessions (5): Q9Y6M0, I3L0U2, I3L2G7, I3L3C7, I3L3F7
UniProt curated annotations — full annotation on UniProt →
Function. Could regulate proteolytic events associated with testicular germ cell maturation.
Subcellular location. Cell membrane.
Tissue specificity. Expressed predominantly in premeiotic testicular germ cells, mostly late pachytene and diplotene spermatocytes.
Similarity. Belongs to the peptidase S1 family.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9Y6M0-1 | 1, L | yes |
| Q9Y6M0-2 | 2, S | |
| Q9Y6M0-3 | 3 |
RefSeq proteins (4): NP_001257381, NP_006790, NP_659205, NP_659206 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001254 | Trypsin_dom | Domain |
| IPR001314 | Peptidase_S1A | Family |
| IPR009003 | Peptidase_S1_PA | Homologous_superfamily |
| IPR018114 | TRYPSIN_HIS | Active_site |
| IPR033116 | TRYPSIN_SER | Active_site |
| IPR043504 |
Pfam: PF00089
UniProt features (20 total): disulfide bond 5, glycosylation site 3, active site 3, propeptide 2, splice variant 2, signal peptide 1, sequence variant 1, chain 1, domain 1, lipid moiety-binding region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9Y6M0-F1 | 85.01 | 0.71 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (3): 82 (charge relay system); 137 (charge relay system); 238 (charge relay system)
Post-translational modifications (1): 288
Disulfide bonds (5): 33–157, 67–83, 171–244, 204–223, 234–262
Glycosylation sites (3): 200, 273, 167
Function
Pathways and Gene Ontology
Reactome pathways
3 pathways
| ID | Pathway |
|---|---|
| R-HSA-163125 | Post-translational modification: synthesis of GPI-anchored proteins |
| R-HSA-392499 | Metabolism of proteins |
| R-HSA-597592 | Post-translational protein modification |
MSigDB gene sets: 47 (showing top):
RIZKI_TUMOR_INVASIVENESS_3D_DN, GOBP_MALE_GAMETE_GENERATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOCC_SIDE_OF_MEMBRANE, GOBP_PROTEOLYSIS, NIKOLSKY_BREAST_CANCER_16P13_AMPLICON, GOMF_PEPTIDASE_ACTIVITY, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, FORTSCHEGGER_PHF8_TARGETS_DN, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, ATM_DN.V1_DN, REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS, BRCA1_DN.V1_UP, STK33_NOMO_DN, KRAS.KIDNEY_UP.V1_DN
GO Biological Process (2): proteolysis (GO:0006508), spermatogenesis (GO:0007283)
GO Molecular Function (5): serine-type endopeptidase activity (GO:0004252), serine-type peptidase activity (GO:0008236), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)
GO Cellular Component (6): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020), side of membrane (GO:0098552)
Reactome top-level categories
Rollup of top-2 pathways:
| Category | Pathways |
|---|---|
| Post-translational protein modification | 1 |
| Metabolism of proteins | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 4 |
| membrane | 2 |
| protein metabolic process | 1 |
| developmental process involved in reproduction | 1 |
| male gamete generation | 1 |
| endopeptidase activity | 1 |
| serine-type peptidase activity | 1 |
| peptidase activity | 1 |
| serine hydrolase activity | 1 |
| binding | 1 |
| hydrolase activity | 1 |
| catalytic activity, acting on a protein | 1 |
| catalytic activity | 1 |
| intracellular anatomical structure | 1 |
| cell periphery | 1 |
| leaflet of membrane bilayer | 1 |
Protein interactions and networks
STRING
932 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| PRSS21 | OAZ3 | Q9UMX2 | 578 |
| PRSS21 | ODF1 | Q14990 | 501 |
| PRSS21 | STEEP1 | Q9H5V9 | 476 |
| PRSS21 | PRSS37 | A4D1T9 | 421 |
| PRSS21 | CCDC42 | Q96M95 | 408 |
| PRSS21 | SPATC1L | Q9H0A9 | 400 |
| PRSS21 | ERLIN2 | O94905 | 393 |
| PRSS21 | PAQR4 | Q8N4S7 | 384 |
| PRSS21 | EIF1 | P41567 | 377 |
| PRSS21 | HNRNPA1L2 | Q32P51 | 377 |
| PRSS21 | FUNDC2 | Q9BWH2 | 371 |
| PRSS21 | PPP1CC | P36873 | 368 |
| PRSS21 | PLD5 | Q8N7P1 | 364 |
| PRSS21 | SPATA6 | Q9NWH7 | 358 |
| PRSS21 | PTTG1 | O95997 | 353 |
| PRSS21 | TACSTD2 | P09758 | 353 |
IntAct
15 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| SERPINB5 | PRSS21 | psi-mi:“MI:0915”(physical association) | 0.640 |
| PRSS21 | SERPINB5 | psi-mi:“MI:0915”(physical association) | 0.640 |
| SERPINB5 | PRSS21 | psi-mi:“MI:0407”(direct interaction) | 0.640 |
| PRSS21 | SERPINB5 | psi-mi:“MI:0403”(colocalization) | 0.640 |
| PARP2 | PRSS21 | psi-mi:“MI:0557”(adp ribosylation reaction) | 0.440 |
| SECTM1 | BCLAF1 | psi-mi:“MI:0914”(association) | 0.350 |
| BST1 | GXYLT2 | psi-mi:“MI:0914”(association) | 0.350 |
| PRSS21 | HSPA5 | psi-mi:“MI:0914”(association) | 0.350 |
| OR14J1 | BST1 | psi-mi:“MI:0914”(association) | 0.350 |
| AFG2A | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| POLD3 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| AFG2B | MMP24OS | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (35): PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-MS), PRSS21 (Affinity Capture-RNA)
ESM2 similar proteins: A1L453, A2VE36, A6NIE9, A8MTI9, E5RG02, O35453, O70169, P08709, P20231, P21845, P50343, P83748, Q14B25, Q14BX2, Q15661, Q16651, Q2F9P2, Q2F9P4, Q2UVH8, Q3UKY7, Q3V0Q7, Q402U7, Q571E5, Q5FBW1, Q5FBW2, Q5M8S2, Q6AXZ6, Q6BEA2, Q6IE62, Q6IE63, Q6UWB4, Q76HL1, Q7RTY5, Q7Z410, Q7Z5A4, Q8BJR6, Q8K4I7, Q8VIF2, Q920S2, Q99MS4
Diamond homologs: A0A1S4GMJ4, A6NIE9, A8JUP7, G3V801, O08762, O42207, O60235, P00741, P00745, P00762, P00765, P03951, P05049, P07477, P07478, P0CW18, P15120, P16292, P16295, P19799, P29786, P29787, P35030, P35039, P69525, P79953, Q14B25, Q14BX2, Q14C59, Q1JRP2, Q27081, Q28278, Q28315, Q28412, Q29463, Q2KJ63, Q2VG86, Q5G265, Q5U405, Q6BEA2
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| PRSS21 | up-regulates | RAD21 | cleavage |
Disease & clinical
Clinical variants and AI predictions
ClinVar
64 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 50 |
| Likely benign | 8 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1416 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 16:2817325:G:GT | donor_gain | 1.0000 |
| 16:2818963:G:GT | donor_gain | 1.0000 |
| 16:2818968:GG:G | donor_gain | 1.0000 |
| 16:2818969:GG:G | donor_gain | 1.0000 |
| 16:2817328:GCCGG:G | donor_gain | 0.9900 |
| 16:2817330:CGGG:C | donor_loss | 0.9900 |
| 16:2817331:GG:G | donor_gain | 0.9900 |
| 16:2817332:GG:G | donor_gain | 0.9900 |
| 16:2817332:GGT:G | donor_loss | 0.9900 |
| 16:2817333:G:GC | donor_loss | 0.9900 |
| 16:2817334:T:A | donor_loss | 0.9900 |
| 16:2817967:G:GG | donor_gain | 0.9900 |
| 16:2818907:T:G | donor_gain | 0.9900 |
| 16:2818911:G:GG | donor_gain | 0.9900 |
| 16:2818932:C:G | donor_gain | 0.9900 |
| 16:2820939:A:AG | acceptor_gain | 0.9900 |
| 16:2820940:C:G | acceptor_gain | 0.9900 |
| 16:2820943:T:G | acceptor_gain | 0.9900 |
| 16:2820980:GGAA:G | acceptor_gain | 0.9900 |
| 16:2821105:GCTTC:G | donor_gain | 0.9900 |
| 16:2821110:G:GG | donor_gain | 0.9900 |
| 16:2821141:G:GT | donor_gain | 0.9900 |
| 16:2821142:A:T | donor_gain | 0.9900 |
| 16:2817333:G:GG | donor_gain | 0.9800 |
| 16:2817335:GAGC:G | donor_loss | 0.9800 |
| 16:2817962:GAAAC:G | donor_gain | 0.9800 |
| 16:2818675:A:AG | acceptor_gain | 0.9800 |
| 16:2818676:G:GA | acceptor_gain | 0.9800 |
| 16:2818676:GCT:G | acceptor_gain | 0.9800 |
| 16:2818907:T:TG | donor_gain | 0.9800 |
AlphaMissense
2032 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 16:2817874:G:C | W55C | 0.998 |
| 16:2817874:G:T | W55C | 0.998 |
| 16:2818947:G:C | W176C | 0.998 |
| 16:2818947:G:T | W176C | 0.998 |
| 16:2821014:T:A | C204S | 0.998 |
| 16:2821015:G:C | C204S | 0.998 |
| 16:2821071:T:A | C223S | 0.998 |
| 16:2821072:G:C | C223S | 0.998 |
| 16:2817872:T:A | W55R | 0.997 |
| 16:2817872:T:C | W55R | 0.997 |
| 16:2817917:A:C | S70R | 0.997 |
| 16:2817919:C:A | S70R | 0.997 |
| 16:2817919:C:G | S70R | 0.997 |
| 16:2817958:C:G | C83W | 0.997 |
| 16:2818834:G:C | A139P | 0.997 |
| 16:2818835:C:A | A139D | 0.997 |
| 16:2818829:A:T | D137V | 0.996 |
| 16:2818945:T:A | W176R | 0.996 |
| 16:2818945:T:C | W176R | 0.996 |
| 16:2821015:G:A | C204Y | 0.996 |
| 16:2821071:T:C | C223R | 0.996 |
| 16:2821072:G:A | C223Y | 0.996 |
| 16:2821429:A:C | S257R | 0.996 |
| 16:2821431:C:A | S257R | 0.996 |
| 16:2821431:C:G | S257R | 0.996 |
| 16:2817878:G:T | G57W | 0.995 |
| 16:2817957:G:A | C83Y | 0.995 |
| 16:2818932:C:G | C171W | 0.995 |
| 16:2821016:C:G | C204W | 0.995 |
| 16:2821073:T:G | C223W | 0.995 |
dbSNP variants (sampled 300 via entrez): RS1000507369 (16:2820072 A>G), RS1000968942 (16:2818001 G>A,C,T), RS1001195163 (16:2816839 G>A,C), RS1001349126 (16:2820643 G>A), RS1002683412 (16:2820302 C>T), RS1003165474 (16:2816616 T>C), RS1003273772 (16:2815428 C>G,T), RS1003502740 (16:2817663 A>G), RS1003803085 (16:2819365 C>A,T), RS1004438407 (16:2819664 G>T), RS1005477675 (16:2820365 G>C), RS1005631667 (16:2820657 C>A,G,T), RS1005806844 (16:2821498 T>A), RS1006372088 (16:2817017 G>A,C), RS1007128468 (16:2821164 C>T)
Disease associations
OMIM: gene MIM:608159 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
14 total (human), top 14 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, affects cotreatment, increases abundance, increases expression | 3 |
| fluorene-9-bisphenol | decreases expression | 1 |
| bisphenol A | decreases methylation, affects cotreatment | 1 |
| arsenite | increases methylation | 1 |
| 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline | decreases expression | 1 |
| bisphenol S | decreases methylation | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | increases expression, increases abundance | 1 |
| Arsenic | affects cotreatment, decreases expression, increases abundance | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Valproic Acid | increases methylation | 1 |
| Cadmium Chloride | decreases expression | 1 |
| Particulate Matter | increases abundance, increases expression | 1 |
Cellosaurus cell lines
1 cell lines: 1 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B2C9 | Abcam HeLa PRSS21 KO | Cancer cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.